#diffuse-large-b-cell-lymphoma

[ follow ]
#car-t-therapy #cart4-34 #ighv4-34 #autoimmune-disease-lupus #b-cell-receptor-signalling #igg1-vs-igm-bcr
Medicine
fromNature
4 days ago

Innovative CAR-T therapy destroys cancer cells without dangerous side effects

CART4-34 T cells target IGHV4-34–bearing cancer B cells, destroying tumors as effectively as CD19 CAR-T while sparing healthy B cells and preserving immune function.
fromNews Center
5 months ago

Understanding Cellular Differences that Impact Lymphoma Development - News Center

"B-cells, which are responsible for producing antibodies, rely on BCRs for survival and growth. While most research has focused on the IgM variant of BCRs, this study sheds light on the lesser-understood IgG1 variant," said Vipul Shukla, PhD, assistant professor of Cell and Developmental Biology, who was co-senior author of the study. "Our lab focuses on understanding the molecular control of B-cell function, which are a key component of the immune system responsible for generating antibodies,"
Cancer
[ Load more ]